Abstract
This short chapter presents the seminal articles that provide the basis for the patients for whom Autonomic Assessment is recommended. The articles are from the medical leadership, including the American Academy of Family Practitioners, American Academy of Neurology, American Diabetes Association, and American Heart Association. The articles identify which diseases or disorders lead to autonomic neuropathy. We know that autonomic neuropathy is late in the progression and leaves few therapy options. We know that autonomic dysfunction is treatable, but is asymptomatic. Therefore, the leadership articles lead to the conclusion that the disease or disorder itself is the “symptom” indicating the need for autonomic assessment. This avoids the issue of screening. So, as long as the patient has been diagnosed with a chronic condition that is identified in the literature as leading to autonomic neuropathy, then they are recommended for periodic Autonomic Assessment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Low PA and the Therapeutics and Technology Assessment Subcommittee Assessment. Clinical autonomic testing report of the therapeutics and technology assessment subcommittee of the American Academy of neurology. Neurology. 1996;46:873–80.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
Goldstein DS. Cardiac sympathetic neuroimaging to distinguish multiple system atrophy from Parkinson disease. Clin Auton Res. 2001;11(6):341–2.
Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol. 2003;2(11):669–76.
Goldstein DS. Cardiac denervation in patients with Parkinson disease. Cleve Clin J Med. 2007;74 Suppl 1:S91–4.
Bloomfield DM, Kaufman ES, Bigger Jr JT, Fleiss J, Rolnitzky L, Steinman R. Passive head-up tilt and actively standing up produce similar overall changes in autonomic balance. Am Heart J. 1997;134(2 Pt 1):316–20.
Grundy SM, Benjamin IJ, Burke GL, Chait A. AHA scientific statement: diabetes and cardiovascular disease, a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.
Joint Editorial Statement by the American Diabetes Association, The National Heart, Lung, and Blood Institute, The Juvenile Diabetes Foundation International, The National Institute of Diabetes and Digestive and Kidney Diseases, The American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation. 1999;100:1132–3.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553–79.
Maser R, Mitchell B, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes, a meta analysis. Diabetes Care. 2003;26(6):1895–901.
Boulton AJM, Vinik AI, Arrezzo JC, Bril V, Feldman EI, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–62.
American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care. 2008;31 Suppl 1:S12–54.
American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36 Suppl 1:S11–66.
Vinik AI, Maser RE, Ziegler D. Neuropathy. The crystal ball for cardiovascular disease. Diabetes Care. 2010;33(7):1688–90.
Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth MS, Grimm RH, Corson MA, Prineas R, The ACCORD Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care. 2010;33:1578–84.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Calles-Escandon J, Lovato L, Simons-Morton D, Kendell D, Pop-Busui R, Cohen R, Bonds D, Fonseca V, Ismail-Beigi F, Banerji M, Failor A, Hamilton B. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics. Diabetes Care. 2010;33:721–7.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Marcia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
Duckworth W, Abraira C, Mortiz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301:1547–55.
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.
American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care. 2010;33 Suppl 1:S11–61.
Ziegler D, Gries F. Alpha-lipoic acid and the treatment of diabetic peripheral autonomic cardiac neuropathy. Diabetes. 1997;46 Suppl 2:S62–6.
Prendergast JJ. Diabetic autonomic neuropathy: part 1. Early detection. Pract Diabetol. 2001;20(1):7–14.
Prendergast JJ. Diabetic autonomic neuropathy: part 2. Treatment. Pract Diabetol. 2001;20(2):30–6.
Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–70.
Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D, SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid. The SYDNEY trial. Diabetes Care. 2003;26(3):770–6.
Ziegler D, Low PA, Litchy WJ, Boulton AJM, Vinik AI, Freeman R, NATHAN 1 Trial Group. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy. Diabetes Care. 2011;34:2054–60.
Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician. 2005;71:2123–30.
Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. U S Endocr Dis. 2007;2:2–9.
Vinik A, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–97.
Low PA, Engstrom JW. Disorders of the autonomic nervous system. In: Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, USA; 2003.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Colombo, J., Arora, R., DePace, N.L., Vinik, A.I. (2015). Medical Specialties’ View of Autonomic System Measurements. In: Clinical Autonomic Dysfunction. Springer, Cham. https://doi.org/10.1007/978-3-319-07371-2_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-07371-2_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-07370-5
Online ISBN: 978-3-319-07371-2
eBook Packages: MedicineMedicine (R0)